Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 336

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 336
---
 C Common Warrant’s fair value on February 5, 2025, the date the down-round feature was triggered, using the current
exercise price at the time of $ and the new exercise price of $. The deemed dividend increased net loss attributable to common
shareholders by $ in the condensed consolidated statement of operations for the three months ended March 31, 2025.

|                                 |     | February 5, 2025 |
|:--------------------------------|:----|-----------------:|
| Exercise price                  |     | $0.80 to $196.00 |
| Term (years)                    |     |              3.0 |
| Expected stock price volatility |     |          109.17% |
| Risk-free rate of interest      |     |            4.19% |

The Company’s Series
C Common Warrants are exercisable into Common Stock and are recorded as equity.

F-24 December 2024 and January 2025 Common Warrants (Successor) On December 23, 2024, the Company issued warrants to purchase an aggregate of 4,203shares of Common Stock to certain investors affiliated with each other to induce investors to exercise their Series A Preferred Warrants for cash (the “December 2024 Common Warrants”). The December 2024 Common Warrants are exercisable for cash at an initial exercise price equal to $ 112.20(as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events). The December 2024 Common Warrants are exercisable beginning six months after the issuance date (the “Initial Exercisability Date”) and expire on the third anniversary of the Initial Exercisability Date. The December 2024 Common Warrants require “buy-in” payments to be made by us for failure to deliver any shares of Common Stock issuable upon exercise. If at the time of exercise of the December 2024 Common Warrants, there is no effective registration statement registering the shares of the Common Stock underlying the December 2024 Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms. On January 6, 2025, the Company issued warrants to purchase an aggregate of 8,193shares of Common Stock to certain investors affiliated with each other to induce investors to exercise their Series A Preferred Warrants for cash (the “January 2025 Common Warrants”). The January 2025 Common Warrants are exercisable for cash at an initial exercise price equal